The U.S. could perhaps enter a new chapter in disclosures related to funding of research via NIH and CDC. STAT News explained the...

Sponsored research is needed to answer some questions. This seems especially true in an age in which government budgets are less than...

Some collections of human are slow learners or have other issues. For example, Coke just took yet another public relations hit for lack...

Retraction Watch. It’s a blog run by two science writers, and one of them is doctor. They look for and write about retractions and...

As we move further and further into an age of massive information sharing, it is logical that "sponsored research" remains a focal point...

Good science depends on access to full data. A new study from the University of California at San Francisco highlights the point. In this...

Law professors and amicus briefs are very much a part of the litigation industry. A recent example is here from am amicus brief on ATS...

Update This August 29, 2011 Financial Times article by Andrew Jack provides an update on big pharma, litigation, disclosures and...

As trust breaks down, demands increase for disclosure. Accordingly, fascinating things are happening in the US as Dodd-Frank act...

Must economists and law professors disclose financial interests and conflicts of interest when they write ? Common sense says: of course...

Medical research often is "sponsored by industry," for obvious reasons. And, in general, more research is good. There are, however, ...

Sponsored research is a short-hand term for situations in which researchers also receive payments from pharma or other entities. Lots of...

A hat tip to David Zaring at The Conglomerate for this post that covers some interesting ground regarding “risk” issue, including...

This article from the Associated Press in the August 19, 2009 issue of the NYT reports on Glaxo’s program in which “ghostwriters” were...

The substance of sponsored medical literature remains a controversial issue. A 2009 article by Mark S. Frankel in the ABA’s SciTech...

This post follows up on a prior post that described the Manville asbestos trust halting its prior practice of licensing its claims data...

The loss of the much discussed Wyeth decision has made this a bad week for pharma. It may get worse. A March 4, 2009 NYT article...

The March 3, 2009, Wall Street Journal includes an interesting article on medical school students wanting disclosures from physicians...